Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 2,377 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed Phase 1 Interventional

Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

NCT01024998
View directory record Official record
Conditions
Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related, Maculopathy, Age-Related, Retinal Degeneration, Retinal Neovascularization, Gene Therapy, Therapy, Gene, Eye Diseases
Interventions
AAV2-sFLT01
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

NCT05397600
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Ophthalmic
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
56
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects

NCT00204893
View directory record Official record
Conditions
Healthy
Interventions
calcium formate
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 24, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

NCT07734064
View directory record Official record
Conditions
Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Interventions
ASP2020
Drug
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Southaven, Mississippi • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Dichoptic Video Treatment for Amblyopia

NCT03825107
View directory record Official record
Conditions
Amblyopia
Interventions
patching, Dichoptic videos
Other
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
3 Years to 7 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

NCT01120132
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
CsA high dose, CsA low dose, PA, Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 24, 2026, 4:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

NCT07661329
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
Interventions
Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)
Drug
Lead sponsor
YS Life Science Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Beverly Hills, California • Inglewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cryoanesthesia for Intravitreal Injections

NCT02872012
View directory record Official record
Conditions
Ocular Anesthesia
Interventions
Cryoanesthesia device, Lidocaine
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

NCT01001195
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2013 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

NCT05394519
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes Mellitus
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Concord, California • Escondido, California • Fullerton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

Radiation and Combination Immunotherapy for Melanoma

NCT03850691
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular), Ipilimumab: Cohort 2 (Ocular)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Burnsville, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 24, 2026, 4:21 AM EDT
Recruiting Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

NCT07282613
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
New Haven, Connecticut • Boynton Beach, Florida • Jacksonville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 4:21 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

NCT07482176
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
79
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 4:21 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Hydrus Microstent as a Quality of Life Consideration

NCT05955118
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Hydrus Microstent
Device
Lead sponsor
InSight Vision Center Medical Group, Inc
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Luminopia One Pilot Study

NCT02782117
View directory record Official record
Conditions
Amblyopia
Interventions
Luminopia One
Device
Lead sponsor
Luminopia
Industry
Eligibility
4 Years to 12 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Maitland, Florida • Chicago, Illinois • Bloomington, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

NCT04734197
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Azusa, California • Hemet, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 24, 2026, 4:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires

NCT00678860
View directory record Official record
Conditions
Eye Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Early Feasibility Study of the Brown Glaucoma Implant in Patients With Severe Visual Impairment or No Light Perceived

NCT03469297
View directory record Official record
Conditions
Glaucoma
Interventions
Brown Glaucoma Implant
Device
Lead sponsor
MicroOptx
Industry
Eligibility
22 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Bloomington, Minnesota • Dayton, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 24, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Head-Cancelled Virtual Reality for Ocular Cranial Nerve Palsies

NCT06417216
View directory record Official record
Conditions
Internuclear Ophthalmoplegia, Palsy, Abducens
Interventions
Head-cancelled virtual reality
Behavioral
Lead sponsor
Kevin Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Jacksonville, Florida • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 24, 2026, 4:21 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

NCT06223958
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
OTX-TKI (axitinib implant), Aflibercept
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
97
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 24, 2026, 4:21 AM EDT
Not listed Not applicable Interventional

Visual Outcomes of Tecnis Symfony Opti-Blue EDOF Intraocular Lens (IOL)

NCT06500416
View directory record Official record
Conditions
Cataract
Interventions
Tecnis Symfony OptiBlue/ Tecnis Symfony OptiBlue toric IOL
Device
Lead sponsor
Coastal Eye Surgeons PLLC
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Greenwich, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 24, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Eye Recovery Automation for Post Injury Dysfunction (iRAPID)

NCT06105892
View directory record Official record
Conditions
Convergence Insufficiency, Traumatic Brain Injury, Concussion, Mild
Interventions
Virtual Eye Rotation Vision Exercise (VERVE), Sham VR Therapy
Device
Lead sponsor
New Jersey Institute of Technology
Other
Eligibility
18 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 24, 2026, 4:21 AM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 24, 2026, 4:21 AM EDT
Completed No phase listed Observational

Assessing Ocular Surface Changes After Changing Glaucoma Medications

NCT00554411
View directory record Official record
Conditions
Glaucoma, Monotherapy With Xalatan From 1 to 18 Months, Ocular Surface Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 24, 2026, 4:21 AM EDT